ΠΠ»Π΅ΡΠΎΡΠ½ΡΠ΅ ΠΈ ΡΡΠ°Π½ΡΠ³Π΅Π½Π½ΡΠ΅ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°Π³ΡΠ΅Π³Π°ΡΠΈΠΈ Π±Π΅Π»ΠΊΠΎΠ², Π²ΠΎΠ²Π»Π΅ΡΠ΅Π½Π½ΡΡ Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π· Π½Π΅ΠΉΡΠΎΠ΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ. Π₯Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΌΡΡΠΈΠ½ΠΎΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ Π³Π°ΠΌΠΌΠ°-ΡΠΈΠ½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠΏΠ°ΡΠΈΠΈ, Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π½Π°Ρ Π² ΡΠ°ΠΌΠΊΠ°Ρ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ, ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠ΄ΠΈΠ»Π° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΡΡΠΎΠΉ ΡΡΠ°Π½ΡΠ³Π΅Π½Π½ΠΎΠΉ Π»ΠΈΠ½ΠΈΠΈ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΌΠΎΠ΄Π΅Π»ΠΈ Π±ΠΎΠ»Π΅Π·Π΅Π½Π΅ΠΉ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π½Π΅ΠΉΡΠΎΠ½Π° Π΄Π»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ Π½ΠΎΠ²ΡΡ ΠΏΠΎΠ΄Ρ ΠΎΠ΄ΠΎΠ² ΠΊ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΈΡ ΡΡΠΆΠ΅Π»ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. ΠΠ΄Π΅Π½ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ ΠΌΠΈΡΠ΅Π½Π΅ΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠΈΠΌΠ΅Π±ΠΎΠ½ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΡΡΠΈΠ½ΠΎΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ Π³Π°ΠΌΠΌΠ°-ΡΠΈΠ½ΡΠΊΠ»Π΅ΠΈΠ½ΠΎΠΏΠ°ΡΠΈΠΈ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- Abercrombie Π. Estimation of the nuclear population from microtomsections// Anat. Ree. 94, 1946. P. 239−247.
- Alberti S., Halfmann R., King O., Kapila A., Lindquist S. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins// Cell. 2009. № 137. P.146−158.
- Alonso Adel Π‘., Mederlyova A., Novak M., Grundke-Iqbal I., Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations// J Biol Chem. V.279(33). P.34 873−34 781.
- Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde//Allg Z Psychiat. 1907. № 64. P.146−148.
- Arai Π’., Hasegawa M., Akiyama H., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis// Biochem Biophys Res Commun. 2006. V. 351. P. 602−11.
- Ayala Y.M., Zago P., D’Ambrogio A. et al. Structural determinants of the cellular localization and shuttling of TDP-43// J Cell Sei. 2008. V.121(Pt 22). P.3778−85.
- Bachurin S., Bukatina E., Lermontova N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer// Ann NY Acad Sei. 2001. Y.939. P. 425−435.
- Bachurin S.O., Shevtsova E.P., Kireeva E.G., Oxenkrug G.F., Sablin S.O. Mitochondria as a target for neurotoxins and neuroprotective agents// Ann NY Acad Sei. 2003. V. 993. P.334−344.
- Bauer P.O., Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies// JNeurochem. 2009. V.110. P. 17 371 765.
- Blair I.P., Williams K.L., Warraich S.T., et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis// J Neurol Neurosurg Psychiatry. 2009. V.81. P. 639−641.
- Bonifati V. Genetics of Parkinson’s disease// Minerva Med. 2005. V.96(3). P.175−186.
- Bosco D.A., Lemay N., Ko H.K. et al. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules// Hum Mol Genet. 2010. V. 19(21). P.4160−4175.
- Brain W.R. Diseases of the nervous system, 6th ed. 1962 Oxford University Press, Oxford, p. 531.
- Bruijn L.I., Houseweart M.K., Kato S., et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1// Science. 1998. V.281. P.1851−1854.
- Brundin P., Melki R., Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases// Nat. Rev. Mol. Cell. Biol. 2010. V. ll (4). P.301−307.
- Buchman Y.L., Adu J., Pinon L.G., Ninkina N.N., Davies A.M. Persyn, a member of the synuclein family, influences neurofilament network integrity// Nat. Neurosci. 1998. V. 1. P. 101 -103.
- Cairns N.J., Neumann M., Bigio E.H., et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions// Am. J. Pathol. 2007. V.171. P. 227−240.
- Caroscio J.T., Calhoun W.F., Yahr M.D. (1994). Prognostic factors in motor neuron disease a prospective study of longevity. In: Rose F.C. (ed). Research progress in motor neuron disease. Pitman, London, pp. 34−43.
- Caughey B., Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders//Annu. Rev.Neurosci. 2003. V.26. P.267−298
- Chai Y., Koppenhafer S.L. Bonini N.M., Paulson H.L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease//J Neurosci. 1999. V.19(23). P.10 338−10 347.
- Chen L., Thiruchelvam M.J., Madura K., Richfield E.K. Proteasome dysfunction in aged human alpha-synuclein transgenic mice// Neurobiol. Dis. 2006. V.23.P.120−126.
- Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease// Trends Neurosci. 1998. V.21. P.249−254.
- Cookson M.R., van der Brag M. Cell systems and the toxic mechanism (s) of alpha-synuclein//Exp Neurol. 2008. № 209. P. 5−11.
- Cummings, J. L. Toward a molecular neuropsychiatry of neurodegenerative diseases// Ann Neurol. 2003. V.54(2). P. 147−154.
- Cushman M., Johnson B.S., King O.D., Gitler A.D., Shorter J. Prion-like disorders: blurring the divide between transmissibility and infectivity// Journal of Cell Science. 2010. № 123. P. l 191−1201.
- Deng H.X., Siddique T. Transgenic mouse models and human neurodegenerative disorders// Arch Neurol. 2000. V.57(12). P.1695−1702.
- Desplats P., Lee H. J., Bae et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sei. USA. 2009. № 106. P.13 010−13 015.
- Doi H., Okamura K., Bauer P.O., et al. RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells// J Biol Chem. 2008. V.283(10). P.6489−6500.
- Dormann D., Rodde R., Edbauer D., et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import// EMBO J. 2010. V.29(16). P.2841−2857.
- Duan W., Li X., Shi J., Guo Y., Li Z., Li C. Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell// Neuroscience. 2010. V. 169(4). P.1621−1629.
- Farrer M., Kachergus J., Forno L., et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications// Ann. Neurol. 2004. V.55, P.174−179.
- Fischer O. Miliare Nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelmassige Veranderung der Hirnrinde bei seniler Demenz// Monatsschr Psychiat Neurol. 1907. № 22. P.361−372.
- Fleming S.M., Salcedo J., Hutson C.B., Rockenstein E., Masliah E., Levine M.S., Chesselet M.F. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein// Neuroscience. 2007. V.142, P.1245−1253.
- Fuentealba R.A., Udan M., Bell S., et al. Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43// J Biol Chem. 2010 V.285(34). P.26 304−26 314.
- Gasser T. Update on the genetics of Parkinson’s disease// Mov. Disord. 2007. V.22 Suppl. 17, P. S343−350.
- Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclei//Neuron. 2002. V.34, P.521−533.
- Goedert M., Spillantini M. G. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies// Mol. Psychiatry. 1998. V.3, P.462−465.
- Gomez-Isla T., Irizarry M.C., Mariash A., et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A3 OP transgenic mice//Neurobiol. Aging. V.24, P.245−258.
- Greten-Harrison B., Polydoro M., Morimoto-Tomita M., et al. a (3y-synuclein triple knockout mice reveal age-dependent neuronal dysfunction// Proc Natl Acad Sci USA. 2010. V. 107(45). P.19 573−19 578.
- Grigorev V.V., Dranyi O.A., Bachurin S.O. Comparative study of action mechanisms of dimebon and memantine on AMP A- and NMDA-subtypes glutamate receptors in rat cerebral neurons// Bull Exp Biol Med. 2003 V.136. P.474−477.
- Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology// Proc Natl Acad Sci USA. 1986 V.83(13). P.4913−4917.
- Guo Y.S., Wu D.X., Wu H.R., et al. Sensory involvement in the SOD1-G93A mouse model of amyotrophic lateral sclerosis// Experimental and Molecular Medicine. 2009. V.41(3). P.140−150.
- He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy// Annu. Rev. Genet. 2009. V.43, P.67−93.
- Hebert L.E., Beckett L.A., Scherr P.A., Evans D.A. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050// Alzheimer Dis. Assoc. Disord. 2001. V. 15. P. 169−173.
- Hicks G.G., Singh N., Nashabi A. et al. FUS deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death// Nat. Genet. 2000. V.24(2). P. 175 179.
- Hutton M., Lendon C.L., Rizzu P., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17// Nature. 1998. V.393(6686). P.702−705.
- Iko Y., Kodama T.S., Kasai N., et al. Domain architectures and characterization of an RNA-binding protein, TLS// J Biol Chem. 2004. № 279. P.44 834−44 840.
- Ito D., Seki M., Tsunoda Y., Uchiyama H., Suzuki N. Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS // Annals of Neurology. 2010. DOI: 10.1002/ana.22 246
- Ji H., Liu Y.E., Jia T., et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing// Cancer Res. 1997. V.57. P.759−764.
- Kabashi E, Valdmanis PN, Dion P, Rouleau GA. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis?// Ann Neurol. 2007. V.62(6). P.553−559.
- Kabashi E., Lin L., Tradewell M.L., et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo// Hum Mol Genet. 2010. V.19(4). P.671−683.
- Kabashi E., Valdmanis P.N., Dion P., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis// Nat Genet. 2008. V.40. P.572−574.
- Kagan B.L., Thundimadathil J. Amyloid peptide pores and the beta sheet conformation// Adv Exp Med Biol. 2010. V.677. P. 150−167.
- Kahle P.J., Neumann M., Ozmen L., et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes// EMBO Rep. 2002. V.3. P.583−588.
- Kahle P J., Neumann M., Ozmen L., et al. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model//Am. J. Pathol. 2001. V. 159. P.2215−2225.
- Kayed R, Head E, Thompson JL, Mclntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003 Apr 18−300(5618):486−9
- Kieburtz K. et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease // Arch Neurol. 2010. V.67(2). P. 154−160.
- Klein R. L., Wang D. B., King M. A. Versatile somatic gene transfer for modeling neurodegenerative diseases//Neurotox Res. 2009. V.16(3). P.329−342.
- Knaevelsrud H., Simonsen A. Fighting disease by selective autophagy of aggregate-prone proteins// FEBS Lett. 2010. V.584(12). P.2635−45.
- Kraemer B.C., Schuck T., Wheeler J.M., et al., Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis// Acta Neuropathol. 2010. 119(4):409−19.
- Kruger R., Kuhn W., Muller T., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease// Nat. Genet. 1998. V.18, P.106−108.
- Kruger R., T. Muller and O. Riess. Involvement of alpha-synuclein in Parkinson’s disease and other neurodegenerative disorders// J. Neural. Transm. 2000. № 107. P. 31−40.
- Kurz A., Perneczky R. Neurobiology of cognitive disorders// Curr. Opin. Psychiatry. 2009. V.22(6). P.546−551.
- Kwong L.K., Uryu K., Trojanowski J.Q., Lee V.M. TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis//Neurosignals. 2008. V.16(l). P.41−51.
- Kwiatkowski T.J., Bosco D.A., Leclerc A.L. et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis // Science. 2009. № 323. P. 1205−1208.
- Lashuel H.A., Lansbury Jr. P.T. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?// Q Rev Biophys. 2006. № 39. P. 167−201.
- Lehman N.L. The ubiquitin proteasome system in neuropathology// Acta Neuropathol. 2009. V. l 18(3). P.329−347.
- Lermontova N.N., Redkozubov A.E., Shevtsova E.F., Serkova T.P., Kireeva E.G., Bachurin S.O. Dimebon and tacrine inhibit neurotoxic action ofbeta-amyloid in culture and block L-type Ca (2+) channels// Bull Exp Biol Med. 2001. № 132. P.107 910−107 983.
- Li W.Q., Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington’s disease// Mol Neurodegener. 2008. № 3. P.15.
- Liu W., Wu Y., Zhou Y. et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers// Cancer Res. 2005. № 65. P. 7635−7643.
- Luk K. C., Song C., O’Brien, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells// Proc. Natl. Acad. Sci. USA. 2009. № 106. P.20 051−20 056.
- Mackenzie I.R., Rademakers R., Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia// Lancet Neurol. 2010. V.9(10). P.995−1007.
- Maroteaux L., Campanelli J.T., Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal// J: Neurosci. 1988. № 8. P.2804−2815.
- Matsuoka Y., Vila M., Lincoln S., et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter// Neurobiol. Dis. 2001. № 8, P.535−539.
- Mattson, M.P. Pathways towards and away from Alzheimer’s disease// Nature. 2004. № 430. P.631−639.
- Matveeva I.A. Action of dimebon on histamine receptors// Farmakol Toksikol. 1983. № 46. P.27−29.
- Mayeux R. Epidemiology of neurodegeneration// Annual review of Neuroscience. 2003. № 26. P.81−104.
- McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q. Clinical and pathological diagnosis of frontotemporaldementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease//Arch Neurol. 2001. № 58. P.1803−1809.
- McNaught K.S., Shashidharan P., Perl D.P., Jenner P., Olanow C.W. Aggresome-related biogenesis of Lewy bodies// Eur J Neurosci. 2002. V.16(ll). P.2136−2148.
- Miller G. Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer’s drug// Science. 2010. V.327, № 5971. P. 1309.
- Mitchell J.D., Borasio G.D. Amyotrophic lateral sclerosis// Lancet. 2007. № 369. P.2031−2041.
- Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion//Nature. 2008. № 451. P.1069−1075.
- Neumann M., Rademakers R., Roeber S., Baker M., Kretzschmar HA., Mackenzie I.R. A new subtype of frontotemporal lobar degeneration with FUS pathology//Brain. 2009. № 132. P.2922−2931.
- Neumann M., Sampathu D.M., Kwong L.K. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis// Science.2006. № 314. P.130−133.
- Nguyen J.V., Soto I., Kim K.Y. et al. Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucomaII Proc Natl Acad Sci U S A. 2011. V. 108(3). P. 1176−1181.
- Nonaka T., Kametani F., Arai T., Akiyama H., Hasegawa M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43// Hum. Mol. Genet. 2009. V.18(18). P.3353−3364. '
- Orr H.T., Zoghbi H.Y. Trinucleotide repeat disorders// Ann Rev Neurosci.2007. № 30. P.575−621.
- Pamphlett R, Luquin N., McLean C., Jew SK., Adams L. TDP-43 neuropathology is similar in sporadic amyotrophic lateral sclerosis with orwithout TDP-43 mutations// Neuropathol Appl Neurobiol. 2009. № 35. P. 222 225.
- Papp M.I., Lantos P.L. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology// Brain. 1994. № 117(Pt 2) P.235−243.
- Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates. 2001. Academic Press, 2nd edition.
- Pesiridis, G. S., Lee, V. M., Trojanowski, J. Q. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis// Hum. Mol. Genet. 2009. № 18. V. R156-R162.
- Pieper A.A., Xie S., Capota E., et al. Discovery of a proneurogenic, neuroprotective chemical// Cell. 2010. № 142. P.39−51.
- Polymeropoulos M.H., Lavedan C., Leroy E., et al. Mutation in the alpha-synuclein gene identifie in families with Parkinson’s disease// Science. 1997. № 276. P. 2045−2047.
- Rademakers R., Stewart H., DeJesus-Hernandez M. et al., FUS gene mutations in familial and sporadic amyotrophic lateral sclerosis// Muscle Nerve. 2010. № 42. P.170−176.
- Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmen L., Haid S., Okochi M., Haass C., Schulz J.B. Sensitivity to MPTP is not increased in Parkinson’s disease-associated mutant alpha-synuclein transgenic mice// J. Neurochem. 2001. № 77. P. l 181−1184.
- Rosen D.R., Siddique T., Patterson D. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis //Nature. 1993. № 362. P. 59−62.
- Saha A.R., Ninkina N.N., Hanger D.P., Anderton B.H., Davies A.M., Buchman V.L. Induction of neuronal death by alpha-synuclein// Eur. J. Neurosci. 2000. № 12. P.3073−3077.
- Samii A., Nutt J.G., Ransom B.R. Parkinson’s disease// Lancet. 2004. № 363. P.1783−1793.
- Shefner J.M., Tyler H.R., Krarup C. Abnormalities in the sensory action potential in patients with amyotrophic lateral sclerosis// Muscle Nerve. 1991. № 14. P.1242−1246.
- Shiina Y., Arima K., Tabunoki H., Satoh J. TDP-43 dimerizes in human cells in culture// Cell Mol Neurobiol. 2010. V.30(4). P.641−652.
- Singleton A.B., Farrer M., Johnson J., et al. Alpha-synuclein locus triplication causes Parkinson’s disease// Science. 2003. № 302. P.841.
- Sipe J. D., Cohen A.S. Review: History of the amyloid fibril// J. Struct. Biol. 2002. № 130. P.88−98.
- Skovronsky D.M., Lee V.M., Trojanowski J.Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications// Annu Rev Pathol. 2006. № 1 P. 151−170.
- Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L., Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies// Neurosci. Lett. 1998. V.251(3). P.205−208.
- Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies// Nature. 1996. № 388. P.839−840.
- Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in amilial and sporadic amyotrophic lateral sclerosis// Science. 2008. № 19. P. 1668−1672.
- Stallings N.R., Puttaparthi K., Luther C.M., Burns D.K., Elliott J.L. Progressive motor weakness in transgenic mice expressing human TDP-43// Neurobiol Dis. 2010. V.40(2) P.404−14.
- Steele J.W., Kim S.H., Cirrito J.R. et al. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo // Mol. Neurodegener. 2009. V.4. P. 51.
- Surguchov A., McMahan B., Masliah E., Surgucheva I. Synucleins in ocular tissues. Mapping of the distributions of a-, P-, and y-synuclein proteins in retina and optic nerve.// J. Neurosci. Res. 2001. № 65. P.68−77.
- Tan E.K., Skipper L.M. Pathogenic mutations in Parkinson disease// Hum. Mutat. 2007. № 28, P.641−653.
- Tudor E.L., Galtrey C.M., Perkinton M.S., et al. Amyotrophic lateral sclerosis mutant vesicle-associated membrane protein-associated protein-B transgenic mice develop TAR-DNA-binding protein-43 pathology// Neuroscience. 2010. V. 167(3). P.774−785.
- Ueda K., Fukushima H., Masliah E., et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease// Proc Natl Acad Sci USA. 1993. № 90. P. l 1282−11 286.
- Unger E.L., Eve D.J., Perez X.A., et al. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of
- A53T mutant human alpha-synuclein in mice// Neurobiol. Dis. 2006. № 21. P. 431−443.
- Urushitani M., Sato T., Bamba H., Hisa Y., Tooyama I. Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP-43// J. Neurosci. Res. 2010. V.88(4). P.784−797.
- Urwin H., Josephs K.A., Rohrer J.D., et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration// Acta Neuropathol. 2010. № 120. P. 33−41.
- Uversky V.N. Mysterious oligomerization of the amyloidogenic proteins// FEBS J. 2010. V.277(14). P.2940−2953.
- Uversky V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation// J. Neurochem. 2007. № 103. P.17−37.
- Vance C., Rogelj B., Hortobagyi et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6// Science. 2009. № 323. P. 1208−1211.
- Verhoef L.G., Lindsten K., Masucci M.G., Dantuma N.P. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins// Hum. Mol. Genet. 2002. № 11. P.2689−2700.
- Wacker J.L., Huang S.Y., Steele A.D., et al. Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington’s disease// J Neurosci. 2009. V.29(28). P.9104−9114
- Wakamatsu M., Ishii A., Iwata S., et al. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice//Neurobiol. Aging. 2008. № 29. P.574−585.
- Wang X., Fan H., Ying Z., Li B., Wang H., Wang G. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system//Neurosci Lett. 2010. V.469(l). P. 112−116.
- Wang, H.Y., Wang, I.F., Bose, J., Shen, C.K. Structural diversity and functional implications of the eukaryotic TDP gene family// Genomics. 2004. № 83. P.130−139.
- Weingarten M.D., Lockwood A.H., Hwo S.Y., Kirschner M.W. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA. 1975. V.72(5). P.1858−1862.
- Westermark P., Benson M.D., Buxbaum J.N., et al. Amyloid fibril protein nomenclature// Amyloid. 2002. № 9. P. 197−200.Westermark, G. T"
- Westermark, P. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis// FEBS Lett. 2009. № 583. P.2685−2690.
- Woodruff-Pak D.S. Animal models of Alzheimer’s disease: therapeutic implications//J. Alzheimers Dis. 2008. V.15(4). P.507−521.
- Wu L.S., Cheng W.C., Hou S.C., Yan Y.T., Jiang S.T., Shen C.K. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis// Genesis. 2010. V.48(l). P.56−62.
- Xu Y.F., Gendron T.F., Zhang Y.J., et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice// J. Neurosci. 2010. V.30(32). P.10 851−10 859.
- Yamashita M., Nonaka T., Arai T., Kametani F. et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models // FEBS Lett. 2009. № 583. P. 2419−2424.
- Yankner Π. A. Mechanisms of neuronal degeneration in Alzheimer’s disease//Neuron. 1996. № 16. P.921−932.
- Yazawa I., Giasson B.I., et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration//Neuron. 2005. № 45. P.847−859.
- Zarranz J.J., Alegre J., Gomez-Esteban J.C., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia// Ann. Neurol. 2004. № 55. P.164−173.
- Zhang H., Kouadio A., Cartledge D., Godwin A.K. Role of gamma-synuclein in microtubule regulation// Exp. Cell. Res. 2010. Oct 23.
- Zhou H., Huang H., Chen D. et al. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene// PLoS Genet 6. 2010. P. el000887.
- Zhou W., Schutzman J., Freed C.R. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: A progressive neurodegenerative model of diffuse Lewy body disease// J. Biol. Chem. 2008. № 283. P.9863−9870.
- Zhou Y., Inaba S., Liu J. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment// Int. J. Oncol. 2006. № 29. P. 289−295.